For many years, artificial intelligence (AI), machine learning (ML) and natural language processing (NLP) had a reputation in the biopharmaceutical industry as flashy buzzwords, with little concrete evidence to back up their promise. Over time, this lack of understanding has created drawn-out anticipation, leaving many skeptical about the true value of these tools.
As the potential of this technology continues to evolve, however, we are seeing dramatic shifts in adoption. Today, organizations in most sectors are developing (sometimes sizable) AI research and implementation groups.
